Luo Jian-jun, Yan Zhi-ping, Wang Jian-hua, Liu Qing-xin, Qu Xu-dong, Zhang Wen
Department of Radiology, Fudan University, Shanghai, China.
Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):535-9.
To evaluate the therapeutic effect of endovascular placement of iodine-125 seed strand and stent combined with transcatheter arterial chemoembolization (TACE) to treat hepatocellular carcinoma (HCC) with tumor thrombus in the main portal vein (MPVTT).
Fifty patients with HCC complicated by MPVTT were enrolled into this study. There were 46 men and 4 women with a mean age of 53.9 years. TACE was performed after the iodine-125 seed strand and self-expandable stent placement in the obstructed segment of the main portal vein (MPV).
Technical success rate was 100% for placement of iodine-125 seed strand and stent in the target segment of MPV. No serious procedure-related complications occurred. The mean follow-up duration was 208.5 d. The mean and median survival time was 370.1 d and 223.0 d, respectively. The 90-, 180-, 360-day cumulative survival rates were 97.5%, 59.3%, and 38.4%, respectively. The mean and median patent time of stent was 524.2 d and 407.4 d, respectively. The 90-, 180-, 360-day cumulative patency rates of stent were 94.9%, 75.2%, and 64.5%, respectively.
Endovascular placement of iodine-125 seed strand and stent combined with TACE is an effective therapy for HCC with tumor thrombus in the main portal vein.
评估血管内植入碘-125籽源链和支架联合经动脉化疗栓塞术（TACE）治疗伴有主门静脉肿瘤血栓（MPVTT）的肝细胞癌（HCC）的疗效。
50例HCC合并MPVTT患者纳入本研究。其中男性46例，女性4例，平均年龄53.9岁。在主门静脉（MPV）梗阻段植入碘-125籽源链和自膨式支架后行TACE。
碘-125籽源链和支架在MPV目标段植入的技术成功率为100%。未发生严重的手术相关并发症。平均随访时间为208.5天。平均生存时间和中位生存时间分别为370.1天和223.0天。90天、180天、360天的累积生存率分别为97.5%、59.3%和38.4%。支架的平均通畅时间和中位通畅时间分别为524.2天和407.4天。支架90天、180天、360天的累积通畅率分别为94.9%、75.2%和64.5%。
血管内植入碘-125籽源链和支架联合TACE是治疗伴有主门静脉肿瘤血栓的HCC的有效方法。
